Molecular Partners . Full-time Employee Directory
Biotechnology ResearchZurich, Switzerland51-200 Employees
Molecular Partners AG is a clinical-stage biotechnology company that designs and develops DARPin therapeutics, a distinct class of customized protein therapeutics intended to address medical challenges not readily tackled by other approaches. The firm is headquartered in Zurich, Switzerland, and maintains an office in Concord, Massachusetts, with a pipeline spanning preclinical and clinical development concentrated on oncology. It pursues its own proprietary programs and also enters into collaborations with major pharmaceutical companies to deliver these therapies to patients. Founded in 2004, Molecular Partners operates from its Swiss and U.S. locations. Recent activity includes partnerships to enable development and manufacturing of Radio-DARPin therapeutics, including a collaboration with Eckert & Ziegler Isotope Products GmbH. The company has reported clinical progress and conference engagement in 2026, including MP0712, a dll3-targeting Radio-DARPin currently dosing in a Phase 1 study, presented at ASCO and SNMMI.